Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Study Purpose

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years - 75 Years
Gender	All

More Inclusion & Exclusion Criteria

Key

Inclusion Criteria:

- Willing and able to understand and provide written informed consent.

- Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

- A diagnosis of discoid lupus erythematosus for ≥ 6 months prior to screening supported by a history of: 1.

A biopsy or. 2. a clinical feature score of ≥ 7 on the DLE Classification Criteria (DLECC) scale.

- Currently active discoid lupus with all the following.

1. Digital photography adjudicated with central reading to confirm a currently active discoid disease lesion. 2. CLASI-A score ≥ 8 related to discoid lesions at Baseline.

- Treatment refractory DLE defined as active disease despite current or historical treatment with a systemic treatment.

- Females are eligible to participate if they are not pregnant or breastfeeding, and meet the contraceptive/barrier requirement(s).

- Males are eligible to participate if they agree to the contraceptive/barrier requirement(s).

- Vaccination status should be up to date per local standards.

Key

Exclusion Criteria:

- Participation in another clinical study with an investigational drug within 4 weeks prior to Randomization or within 5 published half-lives, whichever is longer.

- Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product (IP) or interpretation of participant safety or trial results.

- Weight > 160 kg (352 pounds) at Screening.

- History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or to a previous monoclonal antibody (mAb) or human immunoglobin (Ig) therapy.

- Breastfeeding or pregnant women or women who intend to become pregnant anytime from signing the informed consent form (ICF) through 6 months after receiving the last dose of IP.

- Splenectomy.

- Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks prior to screening through randomization.

- History of clinically significant cardiac disease including unstable angina, myocardial infarction, congestive heart failure within 6 months prior to Randomization; arrhythmia requiring active therapy, except for clinically insignificant extra systoles, or minor conduction abnormalities.

- History of cancer within the past 5 years, except as follows: - In situ carcinoma of the cervix treated with apparent success with curative therapy > 12 months prior to Screening, or.

- Cutaneous basal cell or squamous cell carcinoma treated with curative therapy.

- Any underlying condition that in the opinion of the Investigator significantly predisposes the participant to infection.

- Known history of a primary immunodeficiency or an underlying condition, such as known human immunodeficiency virus (HIV) infection, or a positive result for HIV infection per central laboratory.

- Participants with positive hepatitis B serologic test results.

- All participants will undergo testing for hepatitis C antibody (HCVAb) during Screening.

- Participants who are HCVAb positive will be reflex tested for hepatitis C virus (HCV) RNA and if HCV RNA is positive, the participant is not eligible for the study.

- Active tuberculosis (TB), or a positive interferon-gamma release assay (IGRA) test at screening, unless documented history of appropriate treatment for active or latent TB.

Participants with an indeterminate IGRA test result can repeat the test, but if the repeat test is also indeterminate, they will be excluded.

- Any severe herpes virus family infection (including Epstein-Barr virus, cytomegalovirus (CMV)) at any time prior to Randomization, including, but not limited to, disseminated herpes, herpes encephalitis, recent recurrent herpes zoster (defined as 2 episodes within the last 2 years), or ophthalmic herpes.

- Any herpes zoster, cytomegalovirus (CMV), or Epstein-Barr virus infection that was not completely resolved 12 weeks prior to Randomization.

- Opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within 2 years prior to Randomization.

- Any acute illness or evidence of clinically significant active infection on Day 1.

- Participants who have COVID-19 or other significant infection, or in the judgment of the Investigator, may be at a high risk of COVID-19 or its complications should not be randomized.

- Systemic lupus erythematosus defined by fulfilling 2020 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for systemic lupus erythematosus (SLE).

- Current diagnosis of a systemic connective tissue disease.

- Current inflammatory skin disease other than DLE, that, in the opinion of the Investigator, could interfere with the inflammatory skin assessments and confound the disease activity assessments.

- Exposure to an experimental drug either 30 days, 5 half-lives of the agent, or twice the duration of the biological effect of the agent, whichever is longer, prior to Randomization and through the final trial visit.

- Receipt of a live-attenuated vaccine within 4 weeks prior to Randomization.

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05591222
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 2
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Amgen
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	MD
Principal Investigator Affiliation	Amgen
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Industry
Overall Status	Recruiting
Countries	Argentina, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Poland, United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Discoid Lupus Erythematosus

Additional Details

Approximately 99 participants will be enrolled to receive daxdilimab or placebo administered subcutaneously once every four weeks (Q4W) from Day 1 to Week 44. After week 24 all subjects will be receiving daxbilimab, including those assigned to the placebo arm, Q4W from Week 24 to Week 44. The maximum trial duration per participant is approximately 60 weeks including screening, the 48 weeks for the treatment period where participants will receive daxdilimab or placebo, and approximately 8 weeks for the follow-up period. Safety evaluations will be performed regularly throughout the course of the study. Acquired from Horizon in 2024.

Arms & Interventions

Arms

Placebo Comparator: Placebo/Daxdilimab Arm 1

Administration of placebo Q4W from Day 1 through Week 20 and administration of Daxdilimab Q4W from Week 24 through Week 44.

Experimental: Daxdilimab Arm 2

Administration of Daxdilimab Q4W from Day 1 through Week 44.

Experimental: Daxdilimab Arm 3

Administration of Daxdilimab Q4W from Day 1 through Week 44.

Interventions

Drug: - Placebo/Daxdilimab

Placebo/Daxdilimab will be administered subcutaneously as two injections for each dose.

Drug: - Daxdilimab

Daxdilimab will be administered subcutaneously as two injections for each dose.

Drug: - Daxdilimab

Daxdilimab will be administered subcutaneously as two injections for each dose.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Arkansas Research Trials, North Little Rock, Arkansas

Status

Recruiting

Address

Arkansas Research Trials

North Little Rock, Arkansas, 72117

Site Contact

Shawna Owens

Clinical Trial Finder